top of page

Apogenix’ partner CANbridge announces 67 % five-year overall survival rate compared to 8.2 %


Apogenix’ Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme Patients


  • 83% overall survival at two years vs. 34.3% OS from institutional database

  • 17.95 months median progression-free survival vs.5.8months PFS in historical group

  • Data was presented at the ESMO Sarcoma and Rare Cancers Annual Congress

Full press release:

230327_PR_Apogenix_CANbridge_data
.pdf
Download PDF • 788KB


Comments


bottom of page